Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases

Sun, Jong-Mu; Ahn, Jin Seok; Lee, Soohyeon; Kim, Jung A.; Lee, Jeeyun; Park, Yeon Hee; Park, Hee Chul; Ahn, Myung-Ju; Ahn, Yong Chan; Park, Keunchil

doi:10.1016/j.lungcan.2010.04.003

Cited by 79 publications

(52 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Shorter survival might be the reason for a lower incidence of SREs in SCLC. With regard to the prognostic utility of SREs, some studies found that the survival of NSCLC patients who experienced an SRE was significantly shorter than that of patients who did not experience an SRE [3,20,22]; however, one study reported that SREs were not useful in predicting prognosis [21]. Our present study also reports that there is no difference in survival according to the occurrence of SREs.…”

Section: Discussionsupporting

confidence: 55%

“…In NSCLC, the incidence of SREs is 43-62.6% in patients with bone metastases [10,20,21,22]. We reported a 34.4% rate of SREs in patients with SCLC with bone metastases.…”

Section: Discussionmentioning

confidence: 84%

“…The occurrence of SREs in patients with bone metastases and their prognostic effect have been investigated in several cancers that frequently present with bone metastases, such as NSCLC, prostate cancer, and breast cancer [3,4,10,19,20,21,22]. In NSCLC, the incidence of SREs is 43-62.6% in patients with bone metastases [10,20,21,22].…”

Section: Discussionmentioning

confidence: 99%

“…Several predictive markers for SREs have been reported, mostly in studies of NSCLC [10,21]. In the study by Sun et al [21], patients with characteristics such as a history of smoking, nonadenocarcinoma, poor ECOG PS, and no history of epidermal growth factor receptor tyrosine kinase inhibitor treatment were more likely to have SREs.…”

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Prognostic Factors and Skeletal-Related Events in Patients with Small Cell Lung Cancer with Bone Metastases at the Time of Diagnosis

et al. 2016

View full text Add to dashboard Cite

Background/Objective: The aim of this study was to evaluate the characteristics and prognostic factors of small cell lung cancer (SCLC) with bone metastases. We also investigated the characteristics and predictive factors of skeletal-related events (SREs) in these patients. Materials and Methods: Sixty-one patients who were first diagnosed with SCLC with bone metastases at our institution were included in this retrospective analysis. Results: The overall survival (OS) of patients with bone metastases was shorter than that of patients without bone metastases (4.13 vs. 6.17 months, p = 0.015). Poor Eastern Cooperative Oncology Group (ECOG) performance status (PS; ≥2) and higher serum alkaline phosphatase (ALP; above upper normal limit × 2) were independent poor prognostic factors (p = 0.027 for ECOG PS, p = 0.002 for ALP). More than 1 SRE occurred in 21 patients (34.4%). Cervical spine metastasis, thoracic spine metastasis, pelvic bone metastasis, more than 5 bone metastatic regions and higher serum lactate dehydrogenase were correlated with the occurrence of SREs. Thoracic spinal metastasis was a strong predictive factor for the occurrence of SREs (odds ratio = 5.475; 95% CI: 1.080-27.755). Conclusion: Our study demonstrates the poor prognosis of SCLC patients with bone metastases. Physicians should treat SCLC patients with bone metastases with caution.

show abstract

Section: Discussionsupporting

confidence: 55%

“…In NSCLC, the incidence of SREs is 43-62.6% in patients with bone metastases [10,20,21,22]. We reported a 34.4% rate of SREs in patients with SCLC with bone metastases.…”

Section: Discussionmentioning

confidence: 84%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prognostic Factors and Skeletal-Related Events in Patients with Small Cell Lung Cancer with Bone Metastases at the Time of Diagnosis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…In a recent Korean study, analysis of risk factors for SREs suggested that long-term smoking, nonadenocarcinoma tumors, poor PS and no history of treatment with EGFR TKIs were predictors for SREs [Sun et al 2011]. An important question is whether it is possible to translate these findings to the European population because this study published included Asian patients.…”

Section: Chemotherapy Optionsmentioning

confidence: 99%

Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies

D’Antonio

Passaro

Gori³

et al. 2014

Ther Adv Med Oncol

196

162

View full text Add to dashboard Cite

Bone metastasis in lung cancerLung cancer is the third most common form of cancer to spread to bone. About 30-40% of patients with lung cancer developed bone metastases during the course of their disease; the median survival time of patients with this secondary lesion is 7 months [Coleman, 2001]. These metastases are associated with significant morbidity, loss of functional independence and reduction in quality of life (QOL) [Berenson et al. 2006]. Bone metastasis accounts for 350,000 cancer patients deaths each year [Mundy, 2002] and in lung cancer is associated with increased social costs due to medical care, hospitalization days and cost of treatment [Botteman et al. 2007].In a retrospective study of 259 nonsmall cell lung cancer (NSCLC) patients, the most common site of skeletal metastases was the spine in 50% of patients, followed by the ribs (27.1%), ilium (10%), sacrum (7.1%), femur (5.7%) and humerus, scapula and sternum (2.9%) [Tsuya et al. 2007]. The prognosis was worse in patients with metastasis to the appendicular bone than in patients with metastases only on an axial bone [Sugiura et al. 2008].Pain is usually the first symptom of lung cancer with bone metastases in 80% of patients [Kosteva and Langer, 2008]. Patients with osseous metastases complain of pain at some point with wide variation in pattern and severity [Delaney et al. 2008]. Many factors are implicated in the pain of osseous metastases but a significant portion of the pain seems to be related to osteoclastic bone resorption. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategiesChiara D'Antonio, Antonio Passaro, Bruno Gori, Ester Del Signore, Maria Rita Migliorino, Serena Ricciardi, Alberto Fulvi and Filippo de Marinis Abstract: Bone and brain metastases are a very common secondary localization of disease in patients with lung cancer. The prognosis of these patients is still poor with a median survival of less than 1 year. Current therapeutic approaches include palliative radiotherapy and systemic therapy with chemotherapy and targeted agents. For bone metastasis, zoledronic acid is the most commonly used bisphosphonate to prevent, reduce the incidence and delay the onset of skeletal-related events (SREs). Recently, denosumab, a fully human monoclonal antibody directed against the receptor activator of nuclear factor κB (RANK) ligand inhibiting the maturation of pre-osteoclasts into osteoclasts, showed increased time to SREs and overall survival compared with zoledronic acid. The treatment of brain metastasis is still controversial. Available standard therapeutic options, such as whole brain radiation therapy and systemic chemotherapy, provide a slight improvement in local control, overall survival and symptom relief. More recently, novel target agents such as the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) erlotinib, gefitinib and afatinib have shown activity in patients with brain metastasis. Inter alia, in patients harboring EGFR mutations, the administration of EGFR TKIs is ...

show abstract

Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems

Oster

Lamerato

Glass

et al. 2013

Support Care Cancer

151

105

View full text Add to dashboard Cite

show abstract

Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases

Cited by 79 publications

References 23 publications

Prognostic Factors and Skeletal-Related Events in Patients with Small Cell Lung Cancer with Bone Metastases at the Time of Diagnosis

Prognostic Factors and Skeletal-Related Events in Patients with Small Cell Lung Cancer with Bone Metastases at the Time of Diagnosis

Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies

Natural history of skeletal-related events in patients with breast, lung, or prostate cancer and metastases to bone: a 15-year study in two large US health systems

Contact Info

Product

Resources

About